| DB ID | MyCo_5027 |
| Title | Neutrophil-suppressive activity over T-cell proliferation and fungal clearance in a murine model of Fonsecaea pedrosoi infection |
| Year | 2021 |
| PMID | 34642440 |
| Fungal Diseases involved | Chromoblastomycosis |
| Associated Medical Condition | None |
| Genus | Fonsecaea |
| Species | pedrosoi |
| Organism | Fonsecaea pedrosoi |
| Ethical Statement | The experimental protocols involving animals were previously approved by the Institutional Ethic Committee for Animal Care and Research at the School of Pharmaceutical Sciences (CEUA/FCF Protocol 474). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | IL-6 |
| Biomarker Full Name | Interleukin-6 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | The in vivo experiments were carried out following the recommendations of the ARRIVE Guidelines and the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Briefly, male C57Bl/6 mice at 10–12 weeks of age were obtained from the Animal House Production and Experimentation Facility of the School of Pharmaceutical Sciences of the University of São Paulo. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Fonsecaea pedrosoi is a dematiaceous fungus of the Herpotrichiellaceae family, known as the main agent of chro- moblastomycosis (CBM) disease, a deep and chronic subcutaneous ¬ mycosis. The CBM lesions are characterized by verrucous, erythematous papules, and atrophic lesions in the ¬ skin. Similar to most fungal infections, the treatment of CBM is complex and usually demands multi-drug ¬ administration associated with heat/freezing therapy and, in some cases, ¬ surgery. Moreover, costly and long-term treatments might result in high rates of disease relapse and treatment discontinuation. |
| Technique | Immunological assay |
| Analysis Method | Lymphocyte proliferation assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Lymphocyte proliferation assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
